SCHEMBL1407936

SCHEMBL1407936

O=C(Cc1ccc(-n2cnc3cccnc32)cc1)Nc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
TP53 P04637 3/20 0.52
GRM4 Q14833 1/20 0.47
POLB P06746 1/20 0.43
RORC P51449 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KDR P35968 2/20 0.42
ABL1 P00519 1/20 0.42
LCK P06239 1/20 0.42
CSF1R P07333 1/20 0.42
LYN P07948 1/20 0.42
KIT P10721 1/20 0.42
SRC P12931 1/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
FLT3 P36888 1/20 0.42
BLK P51451 1/20 0.42
ROCK2 O75116 1/20 0.42
SUCNR1 Q9BXA5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407961 0.90 MAPT (0.48) MAPTTP53POLBRORCMEN1
SCHEMBL1408584 0.87 MAPT (0.46) MAPTTP53POLBRORCMEN1
SCHEMBL1408502 0.86 AURKA (0.55) MAPTTP53POLBMEN1KMT2A
SCHEMBL12426552 0.84 POLB (0.49) MAPTTP53POLBRORCROCK2
SCHEMBL1408415 0.83 MAPT (0.43) MAPTTP53POLBRORCMEN1
SCHEMBL1408513 0.83 MAPT (0.45) MAPTTP53POLBRORCMEN1
SCHEMBL1407966 0.83 MKNK2 (0.63) KDRABL1KITSRCFLT3
SCHEMBL1408439 0.83 ABL1 (0.55) ABL1KITSRC
SCHEMBL2202372 0.81 KDR (0.47) MAPTTP53RORCMEN1KMT2A
SCHEMBL1408435 0.81 MCHR1 (0.44) MAPTTP53RORCMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184561-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2012-07-19 US disclosed
US-8030311-B2 Phenylacetamides suitable as protein kinase inhibitors NOVARTIS AG (CH) 2011-10-04 US disclosed
EP-1874770-B1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-09 EP disclosed
US-20080319005-A1 Phenylacetamides Suitable as Protein Kinase Inhibitors NOVARTIS AG (CH) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184561-A1 PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS MAP3K10, MAP3K20, MAP3K9 MAPT 2709/4885TP53 144/4885GRM4 4596/4885
US-20080319005-A1 Phenylacetamides Suitable as Protein Kinase Inhibitors MAP3K20, MAP3K10, MAP3K9 MAPT 2459/4885TP53 188/4885GRM4 4573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.